IntelliCell BioSciences' Stromal Vascular Cell Technology Used For Restorative Cardiac Function With Dr. Zain Khalpey
NEW YORK, April 29, 2014 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous Stromal Vascular Cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The autologous cells were gathered on site with Institutional Review Board approval in accordance with all applicable regulatory requirements. The case was reported in Clinical Communication to the Editor in The American Journal of Medicine Vol.127, No 5, May 2014.
According to Dr. Zain Khalpey's conclusions in the clinical communications to The American Journal of Medicine, "We postulate that the intramyocardial administration of multi-potent adipose-derived stromal vascular fraction cells and their diverse composition guided engraftment in the damaged area, facilitated the cardiomyocyte regenerative properties, and helped improve cardiac function. Because subcutaneous adipose tissue is readily available in most patients, adipose-derived stromal vascular fraction cells present a feasible clinical intervention for cardiac dysfunction. The population complexity, which includes stromal vascular fraction and growth factors, likely promotes repair by recruiting cardiomyocytes. The autologous nature and multi-potency of these cells may contribute to them being ideal for cardiac function restoration."
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a momentous point for Intellicell Biosciences illustrating that its Stromal Vascular Fraction Cells (SVFC) and its technology have clinical promise in the restoration of cardiac function. I believe Dr. Khalpey's theory of injecting the SVFCs intracardiac externally and intravenously under a compassionate IRB, will pave the way for our FDA IND study that will focus on Congestive Heart Failure. This IND study will be important for proving the company's patented technology of Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate. We believe that IntelliCell's Stromal Vascular Fraction Cells injected into the cardiac muscle externally and given intravenously will make a significant clinical difference. We at IntelliCell would like to thank Ms. Stephanie Squicciarini for flying out to Tucson, Arizona with our lab and manufacturing the SVFCs in the operating room for Dr. Khalpey."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Dr. Zain Khalpey according to the University of Arizona website
Born in Africa, Dr. Khalpey completed his medical education in the UK and studied and worked extensively throughout Europe and the United States before deciding to pursue his organ transplantation research at the University of Arizona, the birthplace of the Total Artificial Heart.
In addition to his clinical work at The University of Arizona Medical Center, where he recently was appointed director of the internationally renowned heart transplant program and mechanical circulatory support, Khalpey is involved in numerous research activities, focused mainly in three key areas: bridge to regeneration, organ reconditioning and organogenesis, or the creation of new organs.
The first area, bridge to regeneration, focuses on reducing the number of people who require heart transplants by improving stem cell treatments for failing hearts.
About Arizona College of Medicine according to website
For more than a decade, The University of Arizona Medical Center has been ranked among the nation's best hospitals by U.S. News & World Report.
The University of Arizona Health Network is Arizona's first academic medical network. It includes The University of Arizona Medical Center - University Campus, The University of Arizona Medical Center - Diamond Children's, The University of Arizona Medical Center - South Campus, some 40 clinics, a health plan division and the practice plan for physicians from the University of Arizona College of Medicine. It's been nationally recognized for providing exceptional patient care, teaching new health care professionals and conducting groundbreaking research through the physician-scientists of the University of Arizona College of Medicine.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
SOURCE IntelliCell BioSciences, Inc.